



Final Appraisal Recommendation

Advice No: 2912 – September 2012

Sitagliptin (Januvia[®]▼) 25 mg and 50 mg tablets

Limited submission by Merck Sharp & Dohme Ltd

Recommendation of AWMSG

Sitagliptin (Januvia[®]▼) 25 mg and 50 mg tablets are recommended as an option for use within NHS Wales for the improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl \geq 30 to < 50 ml/min), severe renal impairment (CrCl < 30 ml/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis.

Additional note:

- AWMSG is of the opinion that sitagliptin (Januvia[®]▼) 25 mg and 50 mg tablets may be appropriate for prescribing by all prescribers within NHS Wales for the indication under consideration.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Merck Sharp & Dohme Ltd
Date of first issue	September 2012
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2912:
Sitagliptin (Januvia[®]▼) 25 mg and 50 mg tablets. September 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.